A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome

被引：0
|
作者：
Komrokji, Rami S. [1 ]
Carraway, Hetty E. [2 ]
Germing, Ulrich [3 ]
Wermke, Martin [4 ]
Zeidan, Amer M. [5 ]
Fu, Eric [6 ]
Rueter, Bjoern [7 ]
Burkard, Ute [7 ]
Osswald, Annika [7 ]
Foran, James M. [8 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Dept, Tampa, FL 33612 USA
[2] Cleveland Clin, Taussig Canc Inst, Leukemia Program, Cleveland, OH USA
[3] Heinrich Heine Univ Dusseldorf, Univ Klinikum Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany
[4] Tech Univ, Med Fac Carl Gustav Carus, NCT UCC ECTU, Dresden, Germany
[5] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT USA
[6] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[7] Boehringer Ingelheim Pharm GmbH & Co KG, Biberach, Germany
[8] Mayo Clin, Dept Hematol & Med Oncol, Jacksonville, FL USA
来源：
HAEMATOLOGICA | 2022年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2742 / 2747
页数：6
相关论文
共 50 条
  • [1] A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome
    Komrokji, Rami S.
    Carraway, Hetty E.
    Germing, Ulrich
    Wermke, Martin
    Zeidan, Amer M.
    Fu, Eric
    Rueter, Bjoern
    Burkard, Ute
    Osswald, Annika
    Foran, James M.
    HAEMATOLOGICA, 2022, 107 (11) : 2742 - 2747
  • [2] Randomized Open-Label Phase II Study of Decitabine in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Faderl, Stefan
    Estrov, Zeev
    Godley, Lucy
    Gabrail, Nashat Y.
    Berdeja, Jesus G.
    Nadeem, Ahmed
    Stein, Karen
    Noble, Yvonne
    Kassalow, Laurent
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 1628 - 1629
  • [3] Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Faderl, Stefan
    Estrov, Zeev
    Yang, Hui
    Maddipoti, Sirisha
    Godley, Lucy A.
    Gabrail, Nashat
    Berdeja, Jesus G.
    Nadeem, Ahmed
    Kassalow, Laurent
    Kantarjian, Hagop
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (20) : 2548 - +
  • [4] A Prospective Multicenter Open-Label Study of the Effectiveness of Epoetin Beta for Patients with Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Preliminary Result
    Chuncharunee, Suporn
    Kanitsap, Nonglak
    Suwanban, Tawatchai
    Khuhapinant, Archrob
    Uaprasert, Noppacharn
    Chansung, Kanchana
    Rattarittamrong, Ekarat
    Wongkhantee, Somchai
    Siritanaratanakul, Noppadol
    Norasetthada, Lalita
    Nakorn, Thanyaphong Na
    Charnwiboonsri, Chadchai
    BLOOD, 2016, 128 (22)
  • [5] Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes A Randomized Trial
    Angelucci, Emanuele
    Li, Junmin
    Greenberg, Peter
    Wu, Depei
    Hou, Ming
    Montano Figueroa, Efreen Horacio
    Guadalupe Rodriguez, Maria
    Dong, Xunwei
    Ghosh, Jagannath
    Izquierdo, Miguel
    Garcia-Manero, Guillermo
    ANNALS OF INTERNAL MEDICINE, 2020, 172 (08) : 513 - +
  • [6] Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS)
    Jabbour, Elias
    Sasaki, Koji
    Daver, Naval
    Pemmaraju, Naveen
    DiNardo, Courtney D.
    Kadia, Tapan
    Miller, Darla
    Sukholutsky, Victoria
    Huang, Xuelin
    Borthakur, Gautam
    Estrov, Zeev
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2014, 124 (21)
  • [7] A Phase 1, Open-Label, Multicenter, Dose Escalation Safety Trial of Lyophilized Platelets in Bleeding Thrombocytopenic Patients
    Perez, Jose A. Cancelas
    Ohanian, Maro
    Davenport, Robertson
    Pullarkat, Vinod
    Hervig, Tor Audun
    Broome, Catherine
    Szczepiorkowski, Zbigniew M.
    Pidcoke, Heather
    Pehta, Joan C.
    Fitzpatrick, G. Michael
    TRANSFUSION, 2019, 59 : 8A - 8A
  • [8] Phase I/II open-label, dose-escalation trial of rituximab (Rituxan®) in patients with SLE.
    Anolik, JH
    Campbell, D
    Ritchlin, C
    Holyst, M
    Rosenfeld, S
    Sanz, I
    Young, F
    Felgar, R
    Kunkel, L
    Benyunes, M
    Grillo-Lopéz, A
    Rosenblatt, J
    Looney, RJ
    ARTHRITIS AND RHEUMATISM, 2000, 43 (12): : 2860 - 2860
  • [9] A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium
    Jabbour, Elias J.
    Short, Nicholas J.
    Huang, Xuelin
    Maiti, Abhishek
    Kadia, Tapan M.
    Daver, Naval
    Borthakur, Gautam
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Sasaki, Koji
    Estrov, Zeev
    Verstovsek, Srdan
    Ravandi, Farhad
    Alvarado, Yesid
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    Steensma, David P.
    DeZern, Amy E.
    Roboz, Gail J.
    Miller, Darla
    Dong, Xiao
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2016, 128 (22)
  • [10] Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes
    Stasi, R
    Abruzzese, E
    Lanzetta, G
    Terzoli, E
    Amadori, S
    ANNALS OF ONCOLOGY, 2005, 16 (12) : 1921 - 1927
12345